Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.10.19
Views: 603

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

Prof Marwan Fakih speaks to ecancer at ESMO 2019 in Barcelona about the phase I study of AMG 510, which a novel agent that targets solid tumours with a KRAS G12C mutation. 

He presents the updated safety data in patients with predominately non-small-cell lung cancer (NSCLC) and colorectal cancer.

Prof Fakih also reports that approximately half of the NSCLC patients had an objective response and 79 percent of colorectal cancer patients had disease control.

He emphasises that this agent displays clear activity and is robust in NSCLC. Combinations with AMG 510 are now being explored, including immunotherapy and MEK inhibitors.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation